Tuberculosis
Conditions
Keywords
sweat protein markers in tuberculosis
Brief summary
Sweat proteins are analysed to investigate differences in protein markers in patients with acute tuberculosis and other pulmonary diseases (pneumonia, Bronchitis, chronic obstructive pulmonary disease (COPD)) and healthy individuals. Differences in sweat protein markers in patients with positive and negative tuberculosis Enzyme-linked-immuno-Spot (EliSpot) are investigated. Differences in sweat protein markers in the course of treatment in patients receiving tuberculostatic therapy are investigated.
Interventions
DIAGNOSTIC_TESTanalysis of sweat and serum samples for protein markers
collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients * Ability to understand the purpose of the study, provide signed and dated informed consent by patient or his/her legal representative * In-patients with acute tuberculosis, suspected tuberculosis or other pulmonary diseases (pneumonia, Bronchitis, COPD) Inclusion Criteria Healthy Donors: * negative for Quantiferon- TB Gold Plus Test or ELISpot
Exclusion criteria
* Initiation of tuberculostatic therapy before baseline * Initiation of antibiotic therapy in patients with other pulmonary diseases \> 6 hours before baseline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in protein markers (ESAT-6 and CFP-10 and CRP and Amyloid A2 and C1q) in patients with tuberculosis and other pulmonary diseases | Sweat samples taken at baseline and 2 weeks after baseline | Distinction of patients with acute tuberculosis from patients with other pulmonary diseases by protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)). Analysis done by mass spectrometry and enzyme linked immunosorbent assay (ELIZA). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change of protein markers during tuberculostatic therapy | sweat and blood sweat and blood samples taken at baseline and 2 weeks after initiating tuberculostatic therapy in patients with active tuberculosis | Analysis of protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) during tuberculostatic therapy. Analysis done by mass spectrometry and enzyme linked immunosorbent assay (ELIZA). |
| Differences in protein markers in patients with other pulmonary diseases | sweat and blood samples taken at baseline | Analysis and comparison of protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) in patients with other pulmonary diseases (pneumonia, Bronchitis, COPD). Analysis done by mass spectrometry and enzyme linked immunosorbent assay (ELIZA). |
| Differences in protein markers in patients with positive and negative tuberculosis ELISpot | sweat and blood samples taken at baseline | Analysis and comparison of protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) in patients with positive and negative tuberculosis ELISpot. Analysis done by mass spectrometry and enzyme linked immunosorbent assay (ELIZA). |
Other
| Measure | Time frame | Description |
|---|---|---|
| detection of tuberculostatic drug in sweat samples in patients with active tuberculosis during tuberculostatic therapy | sweat samples taken 2 weeks after initiating tuberculostatic therapy in patients with active tuberculosis | Analysis of sweat protein markers in patients with active tuberculosis during tuberculostatic therapy |
Countries
Switzerland
Outcome results
None listed